Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant

Figure 1 Development of liver parameters during treatment. A: Liver stiffness in correlation to fibrosis was determined by fibroscan at baseline and end of treatment. Measurements are calculated in kPa. Student’s t-test was used to compare categorical characteristics, ^aP-value of < 0.01 was considered to be significant; ALT (B), AST (C) and bilirubin (D) were determined at baseline and end of treatment. Student’s t-test was used to compare categorical characteristics, ^aP-value of < 0.01 was considered to be significant. ¹Wilcoxon signed-rank-test, P≤ 0.05 set as statistic significant. SVR: Sustained viral response; ALT: Alanine aminotransferases; AST: Aspartate aminotransferase.

Figure 2 Safety and adverse events during triple therapy after liver transplantation. Cumulative analysis of moderate and severe side effects related to the treatment period. TW: Treatment week.